Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More
Xconomy
AUGUST 26, 2016
Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. —Pfizer wasn’t done after scooping up Medivation.
40 
Let's personalize your content